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During October 2010–July 2011, 1.0% of pandemic 
(H1N1) 2009 viruses in the United States were oseltamivir 
resistant, compared with 0.5% during the 2009–10 inﬂ  uenza 
season. Of resistant viruses from 2010–11 and 2009–10, 
26% and 89%, respectively, were from persons exposed to 
oseltamivir before specimen collection. Findings suggest 
limited community transmission of oseltamivir-resistant 
virus.
D
uring the 2009–2010 inﬂ   uenza pandemic, when 
pandemic (H1N1) 2009 virus was the predominant 
circulating inﬂ   uenza virus (1), the prevalence of 
oseltamivir-resistant pandemic (H1N1) 2009 viruses in the 
United States was 0.5%. Of the patients with oseltamivir-
resistant virus infection, 89% had been exposed to 
oseltamivir before specimen collection (2). We describe 
patients with oseltamivir-resistant pandemic (H1N1) 2009 
virus infections during the 2010–11 inﬂ  uenza season.
The Study
During October 1, 2010–July 31, 2011, the Centers 
for Disease Control and Prevention (CDC; Atlanta, 
Georgia, USA) asked all state public health laboratories to 
submit pandemic (H1N1) 2009 virus–positive respiratory 
specimens and virus isolates for antiviral susceptibility 
testing. Laboratories were asked to provide the ﬁ  rst  5 
specimens of any type/subtype collected during each 
2-week period for virus isolation. Comprehensive antiviral 
testing, including neuraminidase inhibition (NI) assay, was 
performed on all isolates, and sequencing was performed 
on all isolates with elevated 50% inhibitory concentration 
values. CDC also requested that laboratories provide 5 
additional specimens every 2 weeks for pyrosequencing 
to identify the H275Y substitution in the neuraminidase, 
a change associated with oseltamivir resistance (3). In 
addition to (or instead of) participating in the national 
surveillance, state laboratories in California, Maine, 
Maryland, Minnesota, New York, Texas, and Washington 
performed pyrosequencing on state surveillance specimens 
to detect the H275Y substitution. We included those state-
speciﬁ  c data in the national surveillance data for this report. 
State health departments used a standard case form to 
collect demographic and clinical information for patients 
with oseltamivir-resistant pandemic (H1N1) 2009 virus 
infection and their ill close contacts.
Oseltamivir resistance was determined by use of an 
NI assay or pyrosequencing for the H275Y substitution. 
For NI testing on isolates, we used the NA-Fluor kit 
(Applied Biosystems, Foster City, CA, USA) as described 
(4). We performed pyrosequencing, as described (5), on 
all oseltamivir-resistant pandemic (H1N1) 2009 isolates 
identiﬁ   ed by NI assay to conﬁ   rm the presence of the 
H275Y substitution. We performed pyrosequencing for 
H275Y, without the NI assay, to screen pandemic (H1N1) 
2009 clinical specimens (5). For the national surveillance, 
NI testing was performed at CDC and pyrosequencing was 
performed at CDC and at state laboratories in Wisconsin, 
New York, and California. State laboratories followed 
pyrosequencing protocols provided by CDC; when 
possible, CDC conﬁ  rmed results for resistant viruses by use 
of pyrosequencing and NI assay. Most oseltamivir-resistant 
viruses in this report were included in the weekly FluView 
report prepared by CDC (6).
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We tested a total of 3,652 pandemic (H1N1) 2009 
virus isolates and specimens from every state and the 
District of Columbia; 35 (1.0%) isolates/specimens from 
a total of 18 states were oseltamivir-resistant (Figure). 
Overall, 8 (1.3%) of 609 isolates tested by NI assay and 
27 (1.0%) of 3,043 specimens tested by pyrosequencing 
were resistant to oseltamivir. The state-speciﬁ  c prevalence 
of oseltamivir-resistant pandemic (H1N1) 2009 viruses 
varied; however, the number of viruses and specimens 
tested also varied markedly between states, and several 
states submitted only a few specimens. Forty-four 
states submitted >20 specimens for antiviral resistance 
surveillance. The prevalence of oseltamivir resistance 
among these specimens ranged from 0% to 5.6%. None 
of the 609 pandemic (H1N1) 2009 isolates tested by NI 
assay were resistant to zanamivir. The ranges of 50% 
inhibitory concentration values for oseltamivir-resistant 
and -susceptible isolates were 166.17–230.37 nmol/L and 
0.10–0.80 nmol/L, respectively.
The median age of the 35 patients with oseltamivir-
resistant pandemic (H1N1) 2009 virus infections was 33 
years. Of 34 patients with available information, 26% 
reported receiving oseltamivir before providing a specimen 
for antiviral susceptibility testing (Table 1). Among 33 
patients with a completed case form, 67% had at least 
1 preexisting chronic medical condition, 24% had an 
immunocompromising medical condition, 42% required 
hospitalization, and 9% died. Most patients with oseltamivir-
resistant virus infection for whom housing information was 
available lived in a single-family household. Two siblings 
from 1 household had oseltamivir-resistant virus infection; 
neither child had received oseltamivir.
All oseltamivir-resistant pandemic (H1N1) 2009 viruses 
were identiﬁ  ed from specimens collected during December 
2010–April 2011; the prevalence of resistance did not change 
signiﬁ  cantly over time (test for trend, p = 0.18) (Table 2). In 
addition, the proportion of patients with oseltamivir-resistant 
virus infections who did not have exposure to oseltamivir 
before specimen collection did not change signiﬁ  cantly 
over time (test for trend, p = 0.48); however, the number of 
specimens tested each month was small.
The number of oseltamivir-resistant pandemic (H1N1) 
2009 virus–infected patients was small during the 2009–10 
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Table 1. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009 virus infection, United States, October 1, 2010–
July 31, 2011* 
Characteristic No. with characteristic/total no. (%), n = 35 
Male sex  19/35 (54) 
Exposed to oseltamivir before specimen collection†  9/34 (26) 
Exposed to another person using oseltamivir  0/15 (0) 
Received 2010–11 influenza vaccine  6/22 (27) 
Any chronic medical conditions  22/33 (67) 
  Chronic pulmonary disease, including asthma  10/33 (30) 
  Chronic cardiac disease  6/33 (18) 
 Diabetes  mellitus  8/33(24) 
 Immunocompromising  condition‡  8/33(24) 
 Pregnancy  1/33 (3) 
 Other§  10/33 (30) 
Lived in a single-family household  14/22 (64) 
Lived in a residential facility  1/22 (4) 
Others in the household/residence were ill before patient’s illness  2/15 (13) 
Traveled within 7 d before illness  2/18 (11) 
Hospitalized during influenza illness  14/33 (42) 
 ICU  admission  8/14 (57) 
Died 3/34 (9) 
*The median age of patients was 33 y (range 1 mo–78 y). ICU, intensive care unit. 
†Nine patients began oseltamivir treatment prior to specimen collection; none received oseltamivir chemoprophylaxis. 
‡Includes HIV/AIDS, malignancy, autoimmune disorder, solid organ transplant, stem cell transplant, and history of taking immunosuppressive therapy in 
the past year. 
§Includes morbid obesity, obstructive sleep apnea, chronic liver disease, and neurologic or developmental disorders. 
Figure. Geographic distribution of oseltamivir-resistant pandemic 
(H1N1) 2009 viruses in the United States, October 1, 2010–July 
31, 2011. Numerators are number of oseltamivir-resistant viruses 
identiﬁ   ed by state public health laboratories; denominators are 
number of pandemic (H1N1) 2009–positive specimens submitted 
by each state for susceptibility testing. Gray shading indicates 
states that had >1 infection with oseltamivir-resistant virus.(April 2009–September 2010) and 2010–11 inﬂ  uenza 
seasons. However, the prevalence of oseltamivir-resistant 
virus–infected patients was slightly higher during 2010–11 
compared with 2009–10 (35/3,652 [1.0%] vs. 37/6,740 
[0.5%], respectively, p = 0.02 by χ2 test) (2). Also, during 
2010–11, compared with 2009–10, more patients with 
oseltamivir-resistant virus infection had no history of 
oseltamivir exposure before specimen collection (25/34 
[73.5%] vs. 4/35 [11.4%], respectively; p<0.0001 by χ2 test).
Conclusions
During the 2010–11 US inﬂ  uenza season, the prevalence 
of oseltamivir-resistant pandemic (H1N1) 2009 viruses 
remained low, and most persons with oseltamivir-resistant 
virus infection had no prior oseltamivir exposure. This is a 
notable difference from surveillance ﬁ  ndings both globally 
and in the United States during the 2009–10 season, when 
most patients with oseltamivir-resistant pandemic (H1N1) 
2009 virus infection had a history of oseltamivir exposure, 
and many were severely immunocompromised, a condition 
that may increase the risk for resistance developing during 
oseltamivir therapy (2,7). These data suggest a low level of 
community transmission of oseltamivir-resistant pandemic 
(H1N1) 2009 virus in the United States during the 2010–11 
inﬂ  uenza season. The United Kingdom also reported that the 
proportion of oseltamivir-resistant pandemic (H1N1) 2009 
virus–infected patients without prior oseltamivir exposure 
was higher during 2010–11 than 2009–10 (8).
The increase during the 2010-11 inﬂ  uenza season in the 
proportion of patients with oseltamivir-resistant pandemic 
(H1N1) 2009 virus infections without prior oseltamivir 
exposure causes concern in light of the recent history of 
oseltamivir resistance among seasonal inﬂ  uenza A (H1N1) 
viruses that circulated before pandemic (H1N1) 2009 virus 
emerged. In the United States before the 2007–08 inﬂ  uenza 
season, the prevalence of oseltamivir resistance among 
seasonal inﬂ   uenza A (H1N1) viruses was <1% (9,10). 
However, during the 2007–08 season, the prevalence of 
oseltamivir resistance among seasonal inﬂ  uenza A (H1N1) 
viruses increased to 12%, and by the 2008–09 season, 
resistance dramatically increased to >99% (9,11,12). No 
association was found between this increase in oseltamivir 
resistance and prior oseltamivir use (11,13). Oseltamivir 
resistance in pandemic (H1N1) 2009 and seasonal inﬂ  uenza 
A (H1N1) viruses was conferred by the H275Y substitution 
in the neuraminidase. However, unlike seasonal inﬂ  uenza 
A (H1N1) viruses, which retained susceptibility to the 
M2-blocking adamantanes (amantadine and rimantadine), 
>99% of circulating pandemic (H1N1) 2009 viruses are 
inherently resistant to adamantanes (14). Thus, inhaled 
zanamivir or investigational drugs, such as intravenous 
zanamivir, are the only treatment options for patients 
with oseltamivir-resistant pandemic (H1N1) 2009 virus 
infection.
Our conclusions are limited by the small number of 
patients with oseltamivir-resistant pandemic (H1N1) 2009 
virus infection. Variability in state surveillance and the 
number of specimens tested from each state may also have 
limited the representativeness of our data. Despite these 
shortcomings, our ﬁ  ndings emphasize the importance of 
ongoing surveillance for oseltamivir-resistant pandemic 
(H1N1) 2009 viruses in the United States and globally 
and of close monitoring for changes in the epidemiology 
of oseltamivir resistance among pandemic (H1N1) 2009 
viruses. Updated information about antiviral resistance in 
inﬂ  uenza viruses in the United States is available at www.
cdc.gov/ﬂ  u/professionals/.
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Table 2. Temporal trends of oseltamivir-resistant pandemic (H1N1) 2009 viruses and history of patient exposure to oseltamivir, by
month, United States, October 1, 2010–July 31, 2011 
Year and month of specimen 
collection 
No. specimens 
tested
No. (%) oseltamivir-resistant 
specimens
No. (%) patients with oseltamivir-resistant 
virus but no oseltamivir exposure 
2010 Oct  9  0  0 
2010 Nov  17  0  0 
2010 Dec  172  1 (0.6)  0 
2011 Jan  1,074  6 (0.6)  4 (66.7) 
2011 Feb  1,475  18 (1.2)  15 (83.3) 
2011 Mar  801  9 (1.1)  6 (66.7) 
2011 Apr  95  1 (1.0)  1 (100.0) 
2011 May  8  0  0 
2011 Jun  0  0  0 
2011 Jul  1  0  0 
Total  3,652  35 (1.0)  25 (73.5)* 
*Oseltamivir exposure known for 34 of 35 patients. Resistant Pandemic (H1N1) 2009 Virus Infections
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